Latest On Arbutus Biopharma Corporation (ABUS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-18 02:45 EST | News | Arbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023 | N/A |  |
| 2023-05-04 21:46 EST | News | Arbutus Biopharma Corporation (ABUS) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-04 08:45 EST | News | Arbutus Biopharma GAAP EPS of -$0.10 beats by $0.04, revenue of $6.7M beats by $0.67M | N/A | |
| 2023-04-25 14:16 EST | News | Arbutus sheds 18% after FDA clinical hold on antiviral | N/A | |
| 2023-04-12 00:01 EST | News | Moderna wins appeals court ruling in Arbutus COVID vaccine patent dispute | N/A | |
About Arbutus Biopharma Corporation (ABUS):
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV prot read more...eins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
General
- Name Arbutus Biopharma Corporation
- Symbol ABUS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 76
- Last Split Factor1:5
- Last Split Date2010-11-04
- Fiscal Year EndDecember
- IPO Date2015-08-03
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.arbutusbio.com
Valuation
- Price/Sales (Trailing 12 Mt.) 40.69
- Price/Book (Most Recent Quarter) 2.44
- Enterprise Value Revenue 56.13
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.86
- Next Year EPS Estimate -$0.67
- Next Quarter EPS Estimate -$0.23
- Operating Margin -828%
- Return on Assets -30%
- Return on Equity -73%
- Revenue 6.91 million
- Earnings Per Share -$1.79
- Revenue Per Share $0.09
- Gross Profit -40567000
- Quarterly Earnings Growth 47.5%
Highlights
- Market Capitalization 349.26 million
- EBITDA -71643000
- PE Ratio -9.48
- Analyst Target Price $6.11
- Book Value Per Share $1.23
Share Statistics
- Shares Outstanding 95.58 million
- Shares Float 69.81 million
- % Held by Insiders 2123%
- % Held by Institutions 30.96%
- Shares Short 3.27 million
- Shares Short Prior Month 2.55 million
- Short Ratio 0.94
- Short % of Float 5%
- Short % of Shares Outstanding 4%
Technicals
- Beta 3.05
- 52 Week High $6.48
- 52 Week Low $0.88
- 50 Day Moving Average 3.96
- 200 Day Moving Average 3.56
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Arbutus Biopharma Corporation (ABUS) Dividend Calendar:
Arbutus Biopharma Corporation (ABUS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Arbutus Biopharma Corporation (ABUS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Arbutus Biopharma Corporation (ABUS) Chart:
Arbutus Biopharma Corporation (ABUS) News:
Below you will find a list of latest news for Arbutus Biopharma Corporation (ABUS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Arbutus Biopharma Corporation (ABUS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ABUS Trades:
Arbutus Biopharma Corporation (ABUS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-22 | EFFECT (Notice of Effectiveness) | |
| 2020-09-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-15 | 8-K (Current report) | |
| 2020-09-01 | CT ORDER (Confidential treatment order) | |
| 2020-08-28 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-08-27 | 8-K (Current report) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-07 | 8-K (Current report) | |
| 2020-08-07 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-07 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-07 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-07 | 8-K (Current report) | |
| 2020-07-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-24 | 8-K (Current report) | |
| 2020-07-23 | CT ORDER (Confidential treatment order) | |
| 2020-07-16 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-24 | S-8 (Securities to be offered to employees in employee benefit plans) | |
Arbutus Biopharma Corporation (ABUS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arbutus Biopharma Corporation (ABUS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2123%
Institutional Ownership: 3096%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-07-23 | Michael J. McElhaugh | Chief Business Officer | Sell | 20,000.00 | 5.01 | 100,200.00 | 1,367,457.00 | |
| 2018-11-28 | Mark J. Murray | Director | Buy | 25,000.00 | 1.35 | 33,750.00 | 341,396.00 | |
| 2018-08-13 | Michael J. Sofia | Chief Scientific Officer | Sell | 4,250.00 | 9.51 | 40,435.78 | 1,499,153.00 | |